Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average (2021 - 2025)

Historic Equity Average for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $10.6 million.

  • InMed Pharmaceuticals' Equity Average rose 4528.02% to $10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.6 million, marking a year-over-year increase of 4528.02%. This contributed to the annual value of $11.3 million for FY2025, which is 631.47% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Equity Average of $10.6 million as of Q4 2025, which was up 4528.02% from $12.5 million recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Equity Average high stood at $14.7 million for Q4 2021, and its period low was $1.3 million during Q3 2023.
  • Moreover, its 5-year median value for Equity Average was $10.2 million (2025), whereas its average is $9.8 million.
  • In the last 5 years, InMed Pharmaceuticals' Equity Average tumbled by 8749.59% in 2023 and then skyrocketed by 60080.0% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Equity Average (Quarter) stood at $14.7 million in 2021, then decreased by 13.77% to $12.7 million in 2022, then tumbled by 87.4% to $1.6 million in 2023, then soared by 356.39% to $7.3 million in 2024, then skyrocketed by 45.28% to $10.6 million in 2025.
  • Its Equity Average was $10.6 million in Q4 2025, compared to $12.5 million in Q3 2025 and $10.2 million in Q2 2025.